Bio-Techne Corp is a biotechnology company that specializes in developing and producing high-quality biotechnology tools and reagents for the life sciences market. The company offers a wide range of products, including proteins, antibodies, assays, and diagnostic tools, which are used by researchers and clinical laboratories for various applications, such as drug development, diagnostics, and disease research. With a focus on innovation, Bio-Techne aims to provide cutting-edge solutions that enhance research capabilities and improve patient outcomes in healthcare. Read More
The financial markets are once again in the throes of earnings season, a period that consistently proves to be a crucible for individual stock valuations and a significant driver of broader market sentiment. Recent corporate earnings reports, spanning from late 2024 through the third quarter of 2025, have painted a
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Life sciences company Bio-Techne (NASDAQ:TECH) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates.
Life sciences company Bio-Techne (NASDAQ:TECH)
will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment firm raised its price target on Bio-Techne to $62 from $53. The stock's rise also occurred as the broader market showed strength. Stocks rose after solid earnings reports from major tech companies like Apple and Amazon beat expectations, which seemed to spark a rally in the sector. Bio-Techne's move followed a recent period of volatility, which included a sharp surge of over 18% in the preceding month.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
While the S&P 500 is up 26.5% since April 2025, Bio-Techne (currently trading at $59.58 per share) has lagged behind, posting a return of 19.2%. This may have investors wondering how to approach the situation.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Washington D.C. – September 30, 2025 – Shares of Agilent Technologies (NYSE: A) experienced a significant upward movement today, closing strong amidst breaking news of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE). This surge, echoing similar positive movements for other life sciences companies like
As of September 30, 2025, the financial markets are grappling with the implications of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE), a move signaling a broader governmental push to significantly lower prescription drug costs. While such developments typically send ripples across the entire
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
jumped 5.3% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
